(Q38002357)

26 August 2017

title

Indacaterol: a novel long-acting β(2) -agonist (English)

1 reference

26 August 2017

1 reference

ChEBI release 2020-05-28

Shaunta' M Ray

1

1 reference

26 August 2017

James C McMillen

2

1 reference

26 August 2017

Sarah A Treadway

3

1 reference

26 August 2017

Robert S Helmer

4

1 reference

26 August 2017

Andrea S Franks

5

1 reference

26 August 2017

language of work or name

English

0 references

publication date

12 April 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

32

1 reference

26 August 2017

issue

5

1 reference

26 August 2017

page(s)

456-474

1 reference

Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01025.X

ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01025.X

Novel long-acting bronchodilators for COPD and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01025.X

Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01025.X

Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01025.X

In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01025.X

A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01025.X

Indacaterol, A Novel Once Daily Inhaled beta2-Adrenoreceptor Agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01025.X

Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01025.X

Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01025.X

Efficacy and safety of indacaterol, a new 24-hour beta2-agonist, in patients with asthma: a dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01025.X

Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01025.X

Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01025.X

Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01025.X

24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma: comparison with placebo and formoterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01025.X

24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: a comparison with placebo and salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01025.X

Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01025.X

Bronchodilator effects of indacaterol and formoterol in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01025.X

Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01025.X

Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01025.X

Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01025.X

Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01025.X

Percentiles of inspiratory capacity in healthy nonsmokers: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01025.X

Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01025.X

Indacaterol once-daily is equally effective dosed in the evening or morning in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01025.X

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01025.X

A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01025.X

Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01025.X

10.1002/J.1875-9114.2012.01025.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference